Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology

Personalized Medicine

Volumn 10, Issue 8, 2013, Pages 859-869

  Qin, Rui ^a   Kohli, Manish ^a  

^a MAYO CLINIC   (United States)

Author keywords

adaptive clinical trial; genomic signature; molecular profiling; pharmacogenetic; predictive biomarker

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; BEXAROTENE; BICALUTAMIDE; CABAZITAXEL; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; DOCETAXEL; ENZALUTAMIDE; ERLOTINIB; FLUTAMIDE; GEFITINIB; IMATINIB; LAPATINIB; OLAPARIB; ORTERONEL; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; RADIUM; RADIUM 223; SIPULEUCEL T; SORAFENIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB;

BAYES THEOREM; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG EFFICACY; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE INTERACTION; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; ONCOLOGY; OVARY CANCER; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZATION; REVIEW; STOMACH TUMOR;

EID: 84886454014     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.78     Document Type: Review

References (55)

1. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: Development, science, translation. Ann. Rev. Genom. Hum. Genet. 7, 223-245 (2006
2. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364, 1144-1153 (2011
3. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur. J. Cancer 44, 946-953 (2008
4. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349 (2003
5. Cairncross G, Wang M, Shaw E et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-Term results of RTOG 9402. J. Clin. Oncol. 31, 337-343 (2012
6. Kelley RK, Van Bebber SL, Phillips KA, Venook AP. Personalized medicine and oncology practice guidelines: A case study of contemporary biomarkers in colorectal cancer. J. Natl Compr. Canc. Netw. 9, 13-25 (2011
7. Duffy MJ, ODonovan N, Crown J, Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat. Rev. 37, 151-159 (2011
8. Van De Vijver MJ, He YD, vant Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002
9. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol. 11, 55-65 (2010
10. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin. Proc. 85, 77-86 (2010
11. Dancey JE, Dobbin KK, Groshen S et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 16, 1745-1755 (2010
12. Simon M, Hosking FJ, Marie Y et al. Genetic risk profiles identify different molecular etiologies for glioma. Clin. Cancer Res. 16, 5252-5259 (2010
13. Breiman L. Random forests. Mach. Learn. 45, 5-32 (2001
14. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin. Cancer Res. 10, 6759-6763 (2004
15. Maitournam A, Simon R. On the efficiency of targeted clinical trials. Stat. Med. 24, 329-339 (2005
16. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 23, 2020-2027 (2005
17. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: One size does not fit all. J. Biopharm. Stat. 19, 530-542 (2009
18. Liu A, Liu C, Li Q, Yu KF, Yuan VW. A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations. Clin. Trials 7, 537-545 (2010
19. Wang SJ, ONeill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm. Stat. 6, 227-244 (2007
20. Song Y, Chi GY. A method for testing a prespecified subgroup in clinical trials. Stat. Med. 26, 3535-3549 (2007
21. Freidlin B, Simon R. Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin. Cancer Res. 11, 7872-7878 (2005
22. Jiang W, Freidlin B, Simon R. Biomarker-Adaptive threshold design: A procedure for evaluating treatment with possible biomarker-Defined subset effect. J. Natl Cancer Inst. 99, 1036-1043 (2007
23. Freidlin B, Jiang W, Simon R. The cross-Validated adaptive signature design. Clin. Cancer Res. 16, 691-698 (2010
24. Eickhoff JC, Kim K, Beach J, Kolesar JM, Gee JR. A Bayesian adaptive design with biomarkers for targeted therapies. Clin. Trials 7, 546-556 (2010
25. Lee JJ, Xuemin G, Suyu L. Bayesian adaptive randomization designs for targeted agent development. Clin. Trials 7, 584-596 (2010
26. Korn EL, Freidlin B. Outcome-Adaptive randomization: Is it useful? J. Clin. Oncol. 29, 771-776 (2011
27. Lee JJ, Chen N, Yin G. Worth adaptinǧ Revisiting the usefulness of outcome-Adaptive randomization. Clin. Cancer Res. 18, 4498-4507 (2012
28. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer-A step toward personalized medicine. Clin. Trials 5, 181-193 (2008
29. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97-100 (2009
30. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61, 212-236 (2011
31. Smith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: Results of a Phase II randomized discontinuation trial. J. Clin. Oncol. 31, 412-419 (2013
32. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol. 168, 9-12 (2002
33. Huggins C. Prostatic cancer treated by orchiectomy; the five year results. J. Am. Med. Assoc. 131, 576-581 (1946
34. Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann. Surg. 115, 1192-1200 (1942
35. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321, 419-424 (1989
36. Denis LJ, Keuppens F, Smith PH et al. Maximal androgen blockade: Final analysis of EORTC Phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur. Urol. 33, 144-151 (1998
37. Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 339, 1036-1042 (1998
38. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Prostate Cancer Trialists Collaborative Group. Lancet 355, 1491-1498 (2000
39. Attard G, Reid AH, AHern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742-3748 (2009
40. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011
41. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012
42. Taylor BS, Schultz N, Hieronymus H et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010
43. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013
44. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520 (2004
45. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004
46. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376, 1147-1154 (2010
47. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010
48. Sun J, Chang BL, Isaacs SD et al. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate 68, 1257-1262 (2008
49. Liu W, Laitinen S, Khan S et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Natl Med. 15, 559-565 (2009
50. Mao X, Yu Y, Boyd LK et al. Distinct genomic alterations in prostate cancers in Chinese and western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 70, 5207-5212 (2010
51. Holcomb IN, Young JM, Coleman IM et al. Comparative analyses of chromosome alterations in soft-Tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res. 69, 7793-7802 (2009
52. Ruiz C, Lenkiewicz E, Evers L et al. Advancing a clinically relevant perspective of the clonal nature of cancer. Proc. Natl Acad. Sci. USA 108, 12054-12059 (2011
53. Kumar A, White TA, MacKenzie AP et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl Acad. Sci. USA 108, 17087-17092 (2011
54. Goodin S, DiPaola RS. Cabozantinib in prostate cancer: The beginning of a precision paradigm? J. Clin. Oncol. 31, 401-403 (2013
55. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: Application to cytostatic antineoplastic agents. J. Clin. Oncol. 20, 4478-4484 (2002